Diamyd Medical licenses novel Pain Product

Diamyd Medical reports today that it has acquired an exclusive license for Endomorphin technology that may be used for the treatment of pain, including neuropathic pain, that occurs in diabetes.“In addition to this newly acquired Endomorphin technology, and our exclusive licenses for GAD, we also have an ongoing clinical development program with Enkephalin”, says Elisabeth Lindner, President and CEO of Diamyd Medical. With Enkephalin, GAD and Endomorphin, we have completed our pain portfolio now having products targeting all three major pain receptors. This gives us a strong position in the